CN107530344B - 用于治疗干燥综合征的特定三氟乙基喹啉类似物 - Google Patents

用于治疗干燥综合征的特定三氟乙基喹啉类似物 Download PDF

Info

Publication number
CN107530344B
CN107530344B CN201680022982.1A CN201680022982A CN107530344B CN 107530344 B CN107530344 B CN 107530344B CN 201680022982 A CN201680022982 A CN 201680022982A CN 107530344 B CN107530344 B CN 107530344B
Authority
CN
China
Prior art keywords
syndrome
treatment
mice
sjögren
sjogren
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680022982.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN107530344A (zh
Inventor
R·A·艾伦
F·巴隆
W·A·费伊
S·那亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of CN107530344A publication Critical patent/CN107530344A/zh
Application granted granted Critical
Publication of CN107530344B publication Critical patent/CN107530344B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201680022982.1A 2015-04-21 2016-04-20 用于治疗干燥综合征的特定三氟乙基喹啉类似物 Expired - Fee Related CN107530344B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1506786.1 2015-04-21
GBGB1506786.1A GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use
PCT/EP2016/058810 WO2016170014A1 (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome

Publications (2)

Publication Number Publication Date
CN107530344A CN107530344A (zh) 2018-01-02
CN107530344B true CN107530344B (zh) 2020-03-17

Family

ID=53298950

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680022982.1A Expired - Fee Related CN107530344B (zh) 2015-04-21 2016-04-20 用于治疗干燥综合征的特定三氟乙基喹啉类似物

Country Status (27)

Country Link
US (1) US10493074B2 (https=)
EP (1) EP3285772B1 (https=)
JP (1) JP6721606B2 (https=)
KR (1) KR102627370B1 (https=)
CN (1) CN107530344B (https=)
AR (1) AR105552A1 (https=)
AU (1) AU2016251236B2 (https=)
BR (1) BR112017020591B8 (https=)
CA (1) CA2981631C (https=)
CL (1) CL2017002669A1 (https=)
CO (1) CO2017010573A2 (https=)
CY (1) CY1122572T1 (https=)
DK (1) DK3285772T3 (https=)
EA (1) EA032432B1 (https=)
ES (1) ES2763335T3 (https=)
GB (1) GB201506786D0 (https=)
HR (1) HRP20192273T1 (https=)
HU (1) HUE047162T2 (https=)
IL (1) IL254766B (https=)
LT (1) LT3285772T (https=)
MX (1) MX2017013148A (https=)
MY (1) MY192972A (https=)
PL (1) PL3285772T3 (https=)
PT (1) PT3285772T (https=)
SG (1) SG11201707789YA (https=)
SI (1) SI3285772T1 (https=)
WO (1) WO2016170014A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031569A (zh) * 2004-05-13 2007-09-05 艾科斯有限公司 作为人磷脂酰肌醇3－激酶δ抑制剂的喹唑啉酮
CN101715453A (zh) * 2007-03-23 2010-05-26 安姆根有限公司 杂环化合物及其应用
CN102812013A (zh) * 2009-11-05 2012-12-05 理森制药股份公司 新型苯并吡喃激酶调节剂
CN103153996A (zh) * 2010-09-08 2013-06-12 Ucb医药有限公司 作为激酶抑制剂的喹啉和喹喔啉衍生物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
ES2667173T3 (es) * 2013-06-14 2018-05-09 Gilead Calistoga Llc Inhibidores de fosfatidilinositol 3-quinasa

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031569A (zh) * 2004-05-13 2007-09-05 艾科斯有限公司 作为人磷脂酰肌醇3－激酶δ抑制剂的喹唑啉酮
CN101715453A (zh) * 2007-03-23 2010-05-26 安姆根有限公司 杂环化合物及其应用
CN102812013A (zh) * 2009-11-05 2012-12-05 理森制药股份公司 新型苯并吡喃激酶调节剂
CN103153996A (zh) * 2010-09-08 2013-06-12 Ucb医药有限公司 作为激酶抑制剂的喹啉和喹喔啉衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. Baudouin et al.Current treatments of xerophthalmia in Sjögren’s syndrome.《La revue de médecine interne》.2004,第25卷(第5期),376-382. *
Saba Nayar et al.Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren’s syndrome.《Ann Rheum Dis》.2018,第78卷249-260. *

Also Published As

Publication number Publication date
US20180092921A1 (en) 2018-04-05
SI3285772T1 (sl) 2020-02-28
AR105552A1 (es) 2017-10-18
IL254766B (en) 2020-05-31
EP3285772B1 (en) 2019-10-02
AU2016251236B2 (en) 2018-06-14
US10493074B2 (en) 2019-12-03
SG11201707789YA (en) 2017-11-29
EP3285772A1 (en) 2018-02-28
HRP20192273T1 (hr) 2020-03-06
ES2763335T3 (es) 2020-05-28
MY192972A (en) 2022-09-20
CY1122572T1 (el) 2021-01-27
BR112017020591B1 (pt) 2023-02-07
IL254766A0 (en) 2017-12-31
WO2016170014A1 (en) 2016-10-27
CA2981631C (en) 2023-02-21
CA2981631A1 (en) 2016-10-27
JP2018513862A (ja) 2018-05-31
MX2017013148A (es) 2018-02-21
BR112017020591A2 (pt) 2018-07-03
CL2017002669A1 (es) 2018-05-11
AU2016251236A1 (en) 2017-11-09
EA032432B1 (ru) 2019-05-31
BR112017020591B8 (pt) 2023-05-16
JP6721606B2 (ja) 2020-07-15
KR20170140245A (ko) 2017-12-20
GB201506786D0 (en) 2015-06-03
DK3285772T3 (da) 2020-01-13
PT3285772T (pt) 2020-01-14
CN107530344A (zh) 2018-01-02
HUE047162T2 (hu) 2020-04-28
KR102627370B1 (ko) 2024-01-18
LT3285772T (lt) 2020-01-10
CO2017010573A2 (es) 2018-03-09
PL3285772T3 (pl) 2020-05-18
EA201792318A1 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
Patel et al. Hippocampal TNFα signaling contributes to seizure generation in an infection-induced mouse model of limbic epilepsy
US11344545B2 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
Yao et al. Genetic inactivation of the adenosine A2A receptor exacerbates brain damage in mice with experimental autoimmune encephalomyelitis
US10980812B2 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
Liu et al. Activation of a7 nicotinic acetylcholine receptors prevents monosodium iodoacetate-induced osteoarthritis in rats
Agarwal et al. Subcutaneous repository corticotropin gel for non-infectious panuveitis: reappraisal of an old pharmacologic agent
Zou et al. Heterochromatin inhibits cGAS and STING during oxidative stress-induced retinal pigment epithelium and retina degeneration
CN107530344B (zh) 用于治疗干燥综合征的特定三氟乙基喹啉类似物
CN114206849B (zh) 用于治疗非感染性眼部免疫炎性病症的治疗方法
Li et al. Pan-organ damage analysis in the R848-induced systemic lupus erythematosus mouse model
AU2021360501A9 (en) Method of preventing kidney injury disruption of intestinal lymphatics
JP2025513444A (ja) 自己免疫性皮膚疾患の治療
Kolb et al. Effective Use of Tociluzimab, an Anti-Interleukin 6 Agent for the Treatment of Steroid-Refractory Grade IV Intestinal Acute Graft-Versus-Host Disease in a Child with Sickle Cell Disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Brussels

Patentee after: UCB biopharmaceutical Co.,Ltd.

Address before: Brussels

Patentee before: UCB BIOPHARMA SPRL

CP01 Change in the name or title of a patent holder
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200317